pSivida (NASDAQ: PSDV) announced the completion of the originally targeted enrollment of 120 patients in its pivotal Phase III clinical ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE